AACR Annual Meeting 2027: What's Coming to Cancer Research's Largest Global Gathering

What This Article Covers

The American Association for Cancer Research (AACR) will hold its 2027 Annual Meeting April 2-7, 2027, at the Orange County Convention Center in Orlando, Florida. As the world's largest and most comprehensive cancer research conference, the AACR Annual Meeting is where much of the field's immunotherapy, cell therapy, and CAR-T data gets its first public airing each year. This article covers what's confirmed about the 2027 meeting, what recent AACR annual meetings have delivered for immuno-oncology specifically, and how researchers, clinicians, and informed patients can engage with it.

What AACR Is and Why This Meeting Matters

Founded in 1907, the AACR describes itself as the first and largest cancer research organization dedicated wholly to the disease. It publishes ten peer-reviewed journals, including Cancer Discovery, Cancer Research, and Clinical Cancer Research, and runs numerous specialized conferences throughout the year. But the Annual Meeting is its flagship event, drawing researchers, oncologists, trainees, industry scientists, and advocates to present findings spanning basic, translational, and clinical cancer science. For anyone tracking cell therapy or immunotherapy, the meeting is a reliable early indicator of where the field is heading, since many abstracts later become published, peer-reviewed studies.

What's Confirmed for AACR 2027

According to AACR's official meeting page, the 2027 program carries the theme "Delivering Discovery Science: The Bridge to Breakthrough Therapeutics," with program chairs Sheila A. Stewart (Washington University) and Kurt A. Schalper (Yale School of Medicine). Key logistics confirmed so far:

• Regular abstract submission deadline: November 10, 2026
• Late-breaking and clinical trial abstract deadline: January 6, 2027
• Early registration (lowest rates) closes: December 7, 2026
• Hotel reservation deadline: February 19, 2027

The program will include abstract and poster sessions, continuing medical education (CME) credit opportunities, clinical trial spotlights, career development programming, satellite symposia, and a large exhibit hall. Specific session topics and speaker lineups for 2027 had not yet been published as of this writing; AACR typically releases the detailed program closer to the meeting date.

Why Recent Meetings Matter for Context

The 2026 Annual Meeting, held in San Diego in April, drew more than 23,000 registrants from 74 countries and territories and offered a preview of what large AACR gatherings now routinely surface in immunotherapy and cell therapy: data on BCMA-directed CAR T-cell therapy in high-risk smoldering multiple myeloma, next-generation KRAS inhibitors showing responses in advanced lung cancer, checkpoint inhibitor research covering both efficacy and cardiac risks, new antibody-drug conjugate results in ovarian cancer, and a growing wave of AI tools for predicting immunotherapy response. If recent history holds, the 2027 meeting is likely to feature a similarly dense slate of cell and immune-based therapy updates.

Who Attends and How to Get Involved

Attendance spans academic researchers, oncologists, industry scientists, patient advocates, journalists, and trainees. Registration and abstract submission are handled through AACR's website, and the organization also offers travel and scholar award programs for early-career researchers and underrepresented groups, details for which are published on the official meeting site as the date approaches.

Bottom Line

AACR 2027 is confirmed for April 2-7 in Orlando, and its scale and track record make it one of the most important annual checkpoints for anyone following cancer immunotherapy and cell therapy research. While the detailed scientific program isn't public yet, the abstract deadlines and registration windows are already set, and recent meetings suggest 2027 will again feature substantial CAR-T, checkpoint inhibitor, and emerging-therapy data worth watching.